Altered CVD Risk in Transgender Adults Undergoing Hormone Therapy
Cardiovascular disease risk factors may be altered among transgender adults receiving cross-sex hormone therapy (CSHT).
Cardiovascular disease risk factors may be altered among transgender adults receiving cross-sex hormone therapy (CSHT).
Although there were increased hemoglobin, hematocrit, BMI and lower HDL levels seen with testosterone use.
There may be possible benefits for long-term hormone therapy, but the results are not definitive.
An estimated 14,630 women who were not given the recommended therapy died from cancer recurrence from 2004-2013.
There was a greater discontinuation for white, black and Hispanic patients that were not receiving subsidies.